1. Introduction

The regulation of national genetic research infrastructure development in Morocco concerns the legal, institutional, scientific, and ethical framework governing the establishment and operation of facilities used for genetic research, genomic sequencing, DNA analysis, biobanking, molecular diagnostics, population-genetics studies, and biotechnology innovation.

Genetic research infrastructure includes:

National genomic sequencing laboratories.

Human DNA and genetic sample repositories.

Biobanks and biological specimen databases.

Clinical genetics and molecular diagnostic centres.

University-based genetic research institutions.

Bioinformatics and genomic-data processing facilities.

Public-private biotechnology research partnerships.

Genetic disease surveillance and research networks.

Morocco's regulatory approach must be understood through several overlapping areas of law: constitutional rights, public health, personal-data protection, biomedical research ethics, environmental protection, intellectual property, and international agreements.

An important legal distinction: Morocco does not have one comprehensive statute specifically governing all aspects of national genetic research infrastructure. Instead, different laws and institutional rules regulate particular activities. Consequently, the legal framework must be examined as an interconnected system.

2. Constitutional framework governing genetic research

The Constitution of Morocco of 2011 provides the foundation for developing national genetic research infrastructure.

Three constitutional provisions are particularly relevant.

A. Article 24 – Right to privacy

Article 24 protects every person's private life. This protection is relevant to:

DNA sequencing and genetic profiling.

Storage of identifiable genetic samples.

Disclosure of hereditary disease information.

Sharing genomic information between research institutions.

Unauthorized access to genetic databases.

Genetic information can reveal information not only about an individual but also about biological relatives. Therefore, privacy protection must extend beyond ordinary administrative data security.

B. Article 25 – Freedom of scientific research

Article 25 guarantees freedom of thought, expression, and scientific and technical research.

This provision supports:

Establishment of genomic research centres.

Scientific collaboration between universities.

Development of molecular biology laboratories.

Independent scientific investigation.

Innovation in genetic diagnostics and biotechnology.

C. Article 26 – Government support for scientific development

Article 26 requires public authorities to support cultural, artistic, scientific, and technical research and promote its development.

It provides a constitutional foundation for government investment in national research laboratories, scientific equipment, research training, and genomic innovation.

These constitutional rights must be interpreted together: scientific freedom does not eliminate the obligation to protect human dignity, privacy, and research participants.

cndp.ma+1

3. Principal legislation governing genetic research infrastructure

A. Law No. 28-13 of 2015 – Biomedical research

Central legislation

Law No. 28-13 concerning the protection of persons participating in biomedical research is particularly important for national genetic research infrastructure.

It regulates biomedical research involving human participants and biological materials.

Its relevance includes:

Protection of individuals participating in genetic research.

Ethical and scientific oversight of biomedical investigations.

Requirements relating to informed consent.

Responsibilities of research sponsors and investigators.

Protection of biological samples.

Documentation and monitoring of biomedical research.

Article 31 is particularly significant.

It establishes a minimum 20-year retention period for relevant biomedical research documents. It also addresses the establishment of human biological sample banks.

The provision requires written consent for the conservation and intended use of human biological materials in a biobank. A change in the purpose of use requires new consent and a new declaration to the competent authority.

This is especially important for national genomic repositories because samples collected for one genetic study cannot automatically be reused for unrelated research purposes.

Ma Loi+1

B. Law No. 09-08 of 2009 – Personal data protection

Law No. 09-08 regulates the processing of personal data in Morocco.

It is particularly relevant to:

Genetic databases.

DNA sequencing records.

Electronic medical records.

Genomic research platforms.

Biological sample identification systems.

International genomic-data transfers.

The National Commission for the Control of Personal Data Protection (CNDP) supervises the personal-data protection framework.

Genetic research institutions should establish appropriate procedures for lawful data processing, security, confidentiality, access control, and regulatory declarations or authorisations where applicable.

Genetic information connected to an identifiable individual requires particular care because disclosure may expose hereditary information concerning family members.

Legal implication: A research institution cannot treat the scientific value of genomic information as an unrestricted justification for collecting, storing, or transferring personal data.

cndp.ma+1

C. Law No. 06-22 of 2022 – National health system

Law No. 06-22 establishes the framework for Morocco's national health system.

It is relevant to the institutional development of genetic research because national health-system planning can support:

Modernisation of health facilities.

Development of specialised laboratories.

Improvement of diagnostic services.

Coordination of health institutions.

Research-related healthcare capacity.

This legislation should be distinguished from a dedicated genetic-research statute: it provides a broader health-system framework rather than a complete regulatory code for genomic laboratories.

sante.gov.ma+1

D. Law No. 17-97 – Industrial property protection

Law No. 17-97, as amended, governs industrial property, including patents.

It is relevant to genetic research infrastructure because Moroccan universities and biotechnology companies may develop:

Novel genetic testing technologies.

DNA sequencing equipment.

Biotechnology manufacturing processes.

Diagnostic devices.

Genomic analysis software and related technical inventions.

However, Article 23 excludes discoveries, scientific theories, and mathematical methods from being inventions merely as such. Article 22 requires novelty, inventive step, and industrial applicability.

Consequently, discovering a naturally occurring gene or genetic sequence does not automatically create a patentable invention. A qualifying technical invention must satisfy the statutory patentability conditions.

WIPO+2

4. Institutional framework

Several institutions have important roles in the development and supervision of genetic research infrastructure.

The CNDP is particularly important where genetic research involves identifiable genomic databases or international data transfers.

The Ministry of Health's published regulatory materials identify Law No. 28-13 as a principal instrument governing biomedical research.

sante.gov.ma+2

5. Regulation of national genomic laboratories and research centres

The development of national genetic research infrastructure requires institutions to comply with applicable biomedical research, health-sector, and data-protection requirements.

A. Establishment and authorisation

A genetic research laboratory should identify the legal basis for its activities and determine which regulatory approvals apply.

Relevant considerations include:

Legal registration of the institution.

Authorisation of biomedical research projects where required.

Qualification of investigators and laboratory personnel.

Appropriate laboratory facilities and equipment.

Ethical review and participant protection.

Biosafety and biological-material management.

Data-protection compliance.

A laboratory conducting purely technical research should not automatically be treated as a clinical diagnostic centre. Where it performs medical diagnosis or conducts research involving human participants, additional regulatory requirements may apply.

B. Laboratory quality and scientific reliability

National genetic research facilities should establish quality-management systems covering:

Sample collection and identification.

DNA extraction and purification.

Sequencing accuracy.

Laboratory contamination prevention.

Equipment calibration.

Data validation and reproducibility.

Secure storage of biological materials.

Scientific documentation and audit trails.

These procedures are essential because unreliable genetic results can affect medical decisions, reproductive decisions, family relationships, and scientific conclusions.

C. National biobank development

A national biobank may store DNA, blood, tissue, and other biological specimens for approved scientific purposes.

Article 31 of Law No. 28-13 is especially relevant because it requires written consent for the conservation and intended use of human biological materials in a biobank.

A responsible national biobank should therefore maintain:

A documented consent register.

A specimen identification system.

A record of research purposes.

Access-control procedures.

A withdrawal and destruction policy where legally applicable.

A system for monitoring secondary use.

A record of sample transfers.

A new research purpose cannot simply be assumed to fall within the original consent. The statutory requirements concerning new consent and declaration must be considered.

6. Protection of genetic information and genomic databases

Genetic databases are among the most sensitive components of national research infrastructure.

Law No. 09-08 expressly includes genetic information within the definition of sensitive personal data.

Important provisions include:

An important distinction under Article 12 is that genetic-data processing is generally subject to prior CNDP authorisation, subject to the statutory exception for genetic processing by healthcare professionals for medical purposes such as preventive medicine, diagnosis, and treatment.

This distinction matters when designing a national genomic research database: a research repository should not automatically rely on the exception applicable to qualifying medical processing.

bdj.mmsp.gov.ma+1

Practical security obligations

National genetic databases should implement:

Encryption of genomic records.

Pseudonymisation of research participants.

Restricted researcher access.

Secure backup systems.

Logging of database access.

Controlled international data sharing.

Procedures for reporting and investigating data breaches.

Genetic data should not be considered completely anonymous merely because names and identity numbers have been removed. A person's identity may sometimes be inferred by combining genomic information with other datasets.

7. International collaboration and cross-border genetic research

Morocco's national research infrastructure may collaborate with universities, hospitals, biotechnology companies, and international research organisations.

International cooperation can involve:

Sharing genomic datasets.

Transferring DNA samples.

Joint sequencing projects.

International biobank partnerships.

Cross-border clinical research.

International publication of genetic findings.

However, these activities raise questions of consent, ownership, confidentiality, and regulatory responsibility.

Under Law No. 09-08, the proposed transfer of personal data to foreign countries must be considered within the statutory cross-border transfer framework. The applicable conditions and CNDP procedures must be satisfied.

A research agreement should specify:

The identity of the participating institutions.

The permitted scientific purpose.

The categories of genetic information transferred.

The duration of data retention.

Restrictions on onward disclosure.

Data-security responsibilities.

Rules concerning publication and commercial exploitation.

Procedures for dealing with participant withdrawal.

International collaboration must not become a mechanism for avoiding Moroccan privacy and research-protection requirements.

8. Important case laws and judicial principles

There is an important limitation in the Moroccan legal position: the publicly identifiable legal materials consulted do not establish a developed body of reported Moroccan judgments specifically addressing the establishment of national genomic infrastructure or the operation of genetic biobanks.

Accordingly, the following decisions are relevant comparative authorities. They should not be misrepresented as binding Moroccan judgments.

Case 1. S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Grand Chamber · Applications Nos. 30562/04 and 30566/04 · 4 December 2008

Facts:

The applicants challenged the indefinite retention of their fingerprints, cellular samples, and DNA profiles following criminal proceedings that did not result in convictions.

Legal issue:

Whether retaining DNA samples and profiles without adequate justification violated the right to private life under Article 8 of the European Convention on Human Rights.

Judgment:

The Grand Chamber found a violation of Article 8.

It emphasised the sensitive nature of DNA information, including its capacity to reveal genetic relationships and information about ethnic origins.

Relevance to Morocco:

This judgment provides an important comparative principle for national genetic research infrastructure:

Genetic databases require safeguards against indiscriminate retention.

DNA samples and digital DNA profiles deserve strong privacy protection.

Retention periods should have a legitimate justification.

Individuals' privacy interests must be balanced against public and scientific interests.

bailii.org+1

Case 2. S. and Marper – broader institutional significance

Beyond individual privacy, the judgment has implications for the governance of national databases.

It demonstrates that the creation of a centralised DNA database is not merely a technical decision. It requires a clear legal basis, appropriate retention rules, and safeguards against excessive collection.

For Morocco, this reasoning is relevant when deciding:

Whether a national genomic database should be centralised.

Which categories of samples may be retained.

Who may access genetic information.

Whether samples may be retained after a research project ends.

This is a comparative human-rights principle, not a direct interpretation of Moroccan Law No. 09-08.

Case 3. Moroccan constitutional privacy and scientific freedom

Although a specific reported Moroccan genetic-infrastructure judgment has not been identified, Articles 24–26 of the 2011 Constitution provide the domestic constitutional standards.

Their combined effect is important:

Article 24 protects privacy.

Article 25 guarantees scientific and technical research freedoms.

Article 26 requires public support for scientific and technical research.

A dispute involving unlawful access to genomic information could therefore raise privacy and statutory data-protection questions, while a dispute involving unjustified interference with legitimate scientific research could raise questions concerning constitutional research freedom.

The applicable judicial outcome would depend on the facts, the statutory framework, and the competent court.

Case 4. Moroccan Law No. 28-13 – statutory protection of biological samples

Law No. 28-13 is legislation rather than a judicial precedent, but its Article 31 is directly relevant to disputes concerning biobank management.

For example, suppose a research institution collects biological specimens for a particular genetic study and later uses those specimens for unrelated commercial research without obtaining the required new consent.

The legal questions would include:

Whether the original consent covered the subsequent purpose.

Whether fresh written consent was required.

Whether the relevant declaration was made.

Whether the sponsor or institution complied with its legal responsibilities.

Article 31 provides a statutory basis for assessing such conduct.

Ma Loi+1

9. Recent regulatory development: CNDP recommendations on genomic information (2026)

Important 2026 development

On 11 May 2026, Morocco's CNDP announced the results of a two-and-a-half-year expert working group on the protection of personal data and genomic information.

The group worked during 2023–2025 and produced 17 recommendations.

Participants included genetic experts and representatives associated with the Ministry of Health and Social Protection, the General Directorate of National Security, the Royal Armed Forces, and the Royal Gendarmerie.

The CNDP indicated that its commissioners could subsequently adopt a deliberation following the final discussions.

This development is significant for national genetic research infrastructure because it demonstrates increasing institutional attention to:

Protection of genomic information.

Governance of large-scale genetic datasets.

Security of sensitive biological information.

The wider geopolitical implications of genomic data.

Coordination between scientific and public institutions.

Legal significance: The 17 recommendations should not automatically be treated as enacted legislation or binding regulations. Their legal effect depends on subsequent formal adoption and applicable legal instruments.

cndp.ma

10. Major regulatory challenges

Morocco faces several legal and institutional challenges in developing national genetic research infrastructure.

11. Recommendations for strengthening Morocco's legal framework

Morocco could strengthen its national genetic research infrastructure through the following reforms.

1. National Genetic Research Infrastructure Act

A dedicated statute could establish consistent requirements for genomic laboratories, biobanks, genetic databases, and national sequencing programmes.

2. National biobank regulatory framework

The government could develop detailed rules covering specimen collection, storage, transfer, secondary research use, consent withdrawal, and destruction.

3. National genomic data governance policy

The policy should define the responsibilities of data controllers, researchers, universities, hospitals, and international collaborators.

4. Independent scientific and ethical supervision

Research involving human genetic material should be subject to appropriate scientific and ethical assessment, with clear institutional accountability.

5. Laboratory accreditation

National laboratories should adopt recognised international quality-management and technical standards, including suitable ISO standards where applicable.

6. Protection against genetic discrimination

A specific legal framework could address inappropriate use of genetic information by employers, insurers, commercial organisations, and other third parties.

7. Public-private research partnerships

Government institutions should establish transparent agreements with biotechnology companies, ensuring that public research investment, participant rights, and intellectual property interests are properly protected.

8. International research cooperation

Morocco should develop clear rules for cross-border sample transfers, genomic-data exchange, research partnerships, and equitable benefit-sharing.

12. Conclusion

The regulation of national genetic research infrastructure development in Morocco is based on an interconnected legal framework rather than a single comprehensive genetic research statute.

The most important instruments are:

The 2011 Moroccan Constitution, particularly Articles 24, 25 and 26.

Law No. 28-13 of 2015 on the protection of biomedical research participants.

Law No. 09-08 of 2009 on personal-data protection.

Law No. 06-22 of 2022 concerning the national health system.

Law No. 17-97 on industrial property.

Article 31 of Law No. 28-13 is particularly important for biobanks, while Article 1 and Article 12 of Law No. 09-08 are central to genetic-data protection.

The 2026 CNDP genomic-information recommendations also demonstrate the growing importance of specialised governance in this area.

Ultimately, Morocco's challenge is to develop internationally competitive genetic research facilities while ensuring scientific integrity, informed consent, genetic privacy, institutional accountability, and equitable access to the benefits of genomic research.

13. Principal legal references and research sources

Constitution of Morocco, 2011.

Law No. 28-13 of 2015 – Biomedical Research.

Law No. 09-08 of 2009 – Personal Data Protection.

Moroccan Ministry of Health – National Health System Legislation.

WIPO – Moroccan Law No. 17-97.

CNDP – Protection of Personal Data and Genomic Information, 11 May 2026.

S. and Marper v. United Kingdom (2008).

Research qualification: For academic or legal publication, the latest official Arabic or French versions of legislation, implementing decrees, CNDP decisions, and any subsequent judicial judgments should be checked. The comparative ECHR case above is persuasive research material, not binding Moroccan precedent.